Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SHR-2173 in active lupus nephritis
CTR20254172Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2173 in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by Hengrui Therapeutics. Started Dec 2025; status: active.
02
Drugs
SHR-2173
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20254172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254172.